Filing Flows › Comparisons › HALO vs MGTX
Halozyme Therapeutics vs MeiraGTx Holdings: HALO and MGTX compared
Halozyme Therapeutics is the larger company: $493M of revenue in its latest quarter (Q3 2026) against $321M for MeiraGTx Holdings (Q2 2026). MeiraGTx Holdings is growing faster (87× against +39% a year earlier). MeiraGTx Holdings is more profitable, with an operating margin of 76.0% against 59.8%.
Where the money goes: HALO and MGTX
Halozyme Therapeutics (HALO) · Q3 2026
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.
MeiraGTx Holdings (MGTX) · Q2 2026
MeiraGTx Holdings, Q2 2026: revenue $321M (87× year over year), operating margin 76.0%, net earnings $161M, operating cash flow −$38.5M. The chart follows the revenue to costs, profit and cash.
| Halozyme Therapeutics (HALO) | MeiraGTx Holdings (MGTX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $493M | $321M |
| Revenue growth, Y/Y | +39% | 87× |
| Operating margin | 59.8% | 76.0% |
| Net earnings | $247M | $161M |
| Net margin | 50.1% | 50.0% |
| Operating cash flow | $258M | −$38.5M |
| Free cash flow | $255M | — |
| Market value | $12.7B | $890M |
| P/E | 26.2× | 11.3× |
| Analysts’ mean target | $109.67 | $27.75 |
Where the revenue comes from
Halozyme Therapeutics
- Royalties: $341M (69%)
- Product sales, net: $137M (28%)
- Revenues under collaborative agreements: $14.6M (3%)
MeiraGTx Holdings
- License revenue: $205M (64%)
- Service revenue - related party: $105M (33%)
- Service revenue: $11.9M (4%)
Questions
Which is bigger, Halozyme Therapeutics or MeiraGTx Holdings?
Halozyme Therapeutics is the larger company: $493M of revenue in its latest quarter (Q3 2026) against $321M for MeiraGTx Holdings (Q2 2026).
Is Halozyme Therapeutics or MeiraGTx Holdings growing faster?
MeiraGTx Holdings is growing faster (87× against +39% a year earlier).
Which is more profitable, Halozyme Therapeutics or MeiraGTx Holdings?
MeiraGTx Holdings is more profitable, with an operating margin of 76.0% against 59.8%.
More: Halozyme Therapeutics earnings · how Halozyme Therapeutics makes money · MeiraGTx Holdings earnings · how MeiraGTx Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.